首页> 美国卫生研究院文献>Haematologica >Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

【2h】

Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

机译：缓解后治疗对65-70岁的从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThere is no standard post-remission therapy in older patients with acute myeloid leukemia.

机译：背景老年急性髓性白血病患者尚无标准的缓解后治疗方法。

著录项

期刊名称 Haematologica
作者
Raphael Itzykson; Claude Gardin; Cécile Pautas; Xavier Thomas; Pascal Turlure; Emmanuel Raffoux; Christine Terré; Pierre Fenaux; Sylvie Castaigne; Hervé Dombret; Nicolas Boissel;
展开▼
作者单位

展开▼
年(卷),期 2011(96),6
年度 2011
页码 837–844
总页数 8
原文格式 PDF
正文语种
中图分类血液学检验;
关键词
acute myeloid leukemia post-remission therapy older patients;

机译：急性髓细胞性白血病;缓解后治疗;老年患者;

相似文献

外文文献
中文文献
专利

1. Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria | Haematologica [J] . Raphael Itzykson, Claude Gardin, Cécile Pautas, Haematologica . 2011,第6期

机译：缓解后治疗对65-70岁从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较|血液学
2. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy [J] . DeAngelo Daniel J., Sekeres Mikkael A., Ottmann Oliver G., Clinical lymphoma, myeloma & leukemia . 2015,第Suppla1期

机译：III阶段随机试验的Volasertib与低剂量的溶剂（LDAC）与安慰剂加上LDAC，= 65岁的患者，= 65岁，急性未经治疗，急性髓性白血病（AML）不合适，不合适
3. Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age = 60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial [J] . Foran James M., Sun Zhuoxin, Paietta Elisabeth, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在完全缓解时，通常检测到最小的残留疾病（MRD）在急性髓性白血病（AML）患者年龄＆ = 60年来基于缓解后处理策略显着影响结果：对ECOG-acrin（EA）E2906的前瞻性分析第三阶段试验
4. Computationally derived cytological image markers for predicting risk of relapse in acute myeloid leukemia patients following bone marrow transplantation [C] . Sara ArabYarmohammadi, Zelin Zhang, Patrick Leo, Conference on Medical Imaging: Digital Pathology . 2020

机译：计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
5. Development of a Selective and Stable Reactive Oxygen Species-activated Anti-Acute Myeloid Leukemia Agent and Localizing DNA Aptamer [D] . Earnest, Kaylin Grace. 2018

机译：开发一种选择性和稳定的活性氧物质 - 活化的抗急性髓性白血病药剂和定位DNA适体
6. Clinical Trials and Observations: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [O] . Stefan Faderl, Farhad Ravandi, Xuelin Huang, -1

机译：临床试验和观察：氯法拉滨与氯法拉滨加小剂量阿糖胞苷作为一线疗法的随机研究用于60岁及以上的急性髓细胞白血病和高危骨髓增生异常综合症患者
7. Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria [O] . Itzykson, Raphael, Gardin, Claude, Pautas, Cécile, 2011

机译：缓解后治疗对65-70岁从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较

Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

摘要

著录项

相似文献

相关主题

期刊订阅